On the 26th, the sixth batch of countries organized a special project for centralized drug procurement of insulin to open bids in Shanghai, and the results of the proposed selection were produced.

The average price of the products to be selected is reduced by 48%, which is expected to save 9 billion yuan each year.

The demand for centralized insulin production is about 210 million

The amount involved is about 17 billion yuan

  This collection covers the second- and third-generation insulins commonly used in clinical practice, including 16 varieties with generic names.

The purchase demand of medical institutions nationwide in the first year is about 210 million. Based on the pre-collection price, the purchase amount involved is about 17 billion yuan.

Pharmaceutical companies actively participated in this centralized procurement, and 11 companies participated in the bidding.

  All domestic and foreign enterprises in this centralized procurement have their products selected.

The products to be selected include both well-known enterprise products commonly used by medical institutions and emerging enterprise products. While reducing the falsely high prices, they have achieved a high degree of matching with actual clinical needs.

This centralized procurement optimizes the rules based on the characteristics of insulin

  This centralized procurement adhered to the "integration of recruitment and procurement, linked to volume and price". Based on the successful experience of the early-stage drug and consumable centralized procurement exploration, the procurement rules were optimized for the characteristics of insulin:

  Fully respect the clinical choice, maintain the stability of clinical medication, and reduce the risk of substitution;

  Different generic names of insulin with the same therapeutic purpose and clinical mechanism of action are combined to compete, taking into account the needs of clinical use and the sufficiency of competition;

  Attaches great importance to the supply of selected products, according to the characteristics of insulin production and use, through the bottom-line survey of production capacity, and sufficient production preparation time, etc., multiple measures are taken to ensure the supply.

  Taking the commonly used insulin glargine as an example, from an average of 180 yuan per tube to about 70 yuan per tube, each patient can save about 4,000 yuan per year.

  Because insulin needs to be used for a long time, the falsely high price brings a heavy burden to patients.

This special insulin procurement is the first time that the state organizes centralized drug procurement to expand into the field of biological drugs. It is an important milestone in the process of centralized procurement reform. It not only promotes the return of insulin prices to a reasonable level and benefits more patients, but also contributes to the improvement of the centralized procurement system and the realization of reforms. Goals are also important.

Watch more news


  The fifth batch of national centralized procurement of drugs has been launched nationwide in October

  It is understood that the results of the fifth batch of nationally-organized drugs for centralized procurement have been implemented nationwide in October. Generally speaking, the procurement of selected drugs for each batch is progressing smoothly, fulfilling the promise of mass procurement, and allowing the masses to use price reductions. After the selected drugs.

  According to the data provided by the National Medical Insurance Administration, the first three batches of nationally-sourced drugs have completed the procurement cycle of more than one year, and the actual annual purchases of the selected products have reached about 2.4 times the annual contracted purchases, and the purchases of the selected products accounted for the same generic drugs. The proportion of procurement volume exceeds 80%.

As of the end of October, the fourth batch of centralized procurement has been implemented for 5 months, and the procurement progress is close to 90% of the annual agreed procurement volume.